CJC-1295 (No DAC)

At a glance

Material class

short-acting GHRH analogue

Catalog category

growth hormone

Molecular confirmation

Verified by MS

Appearance

Lyophilised powder; inspect vial and COA before use

Primary research themes

pulsatile GH-axis models without DAC modification

Why researchers choose our CJC-1295 (No DAC)

• Third-party HPLC-verified purity ≥99.0% on every qualifying batch, with COA documentation published on-page when available or available from support by batch reference.
• Lyophilised vial format supports controlled storage, reconstitution, and aliquoting workflows.
• Mass confirmation and chromatographic identity checks are used to support batch traceability.
• Canadian shipping and clear labelling help research teams keep custody records organized.

Primary target context

Research teams usually evaluate CJC-1295 (No DAC) through pulsatile GH-axis models without DAC modification. Experimental interpretation should start with the intended receptor, enzyme, binding partner, or formulation role before comparing outcome markers.

Downstream signalling

Downstream readouts for CJC-1295 (No DAC) depend on the model system, but commonly include pathway activation markers, transcript or protein expression, tissue histology, and time-course response compared with vehicle controls.

Model selection

In-vitro assays can isolate binding or signalling behaviour, while rodent or ex-vivo models may capture tissue-level response. Study design should separate compound-specific effects from diluent, handling, and batch variables.

Controls and limitations

Because CJC-1295 (No DAC) is supplied as a research material, interpretation depends on validated controls, documented storage, matched vehicle arms, and batch-specific COA review. Avoid extrapolating model findings outside the study design.

Before reconstitution

• Keep sealed vials cold, dry, and protected from light until use.
• Allow the vial to equilibrate before opening to reduce condensation on the stopper or cake.
• Inspect label, lot number, cake appearance, and COA before assigning the material to a study.

Reconstitution

• Use sterile diluent compatible with the study design and the product-specific handling sheet.
• Introduce diluent slowly down the vial wall and swirl gently until dissolved.
• Record concentration, diluent, operator, date, and any deviations in the lab notebook.

After reconstitution

Short-term

2–8 °C, protected from light, using aseptic handling.

Long-term

Store lyophilised material at freezer conditions unless the COA or handling sheet states otherwise.

Freeze / thaw

Avoid repeated freeze-thaw cycles; aliquot when validated by the protocol.

What's on the COA

• Batch or lot number matched to the vial label
• HPLC chromatogram and reported purity
• Mass confirmation or identity check when applicable
• Appearance and solubility observations
• Manufacture, release, or re-test date where available

CJC-1295 (No DAC) vs. CJC-1295 (DAC)

CJC-1295 (No DAC) is positioned around GHRH research, while CJC-1295 (DAC) is typically cross-shopped for a related but distinct research angle. Select between them by receptor/pathway target, literature model, handling requirements, and whether the study design needs a single compound or a comparative arm.

CJC-1295 (No DAC) vs. Ipamorelin

CJC-1295 (No DAC) is positioned around GHRH research, while Ipamorelin is typically cross-shopped for a related but distinct research angle. Select between them by receptor/pathway target, literature model, handling requirements, and whether the study design needs a single compound or a comparative arm.